These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8149495)

  • 1. Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet.
    Shivapurkar N; Tang Z; Ferreira A; Nasim S; Garett C; Alabaster O
    Carcinogenesis; 1994 Apr; 15(4):775-8. PubMed ID: 8149495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane.
    Kishimoto Y; Morisawa T; Hosoda A; Shiota G; Kawasaki H; Hasegawa J
    J Exp Clin Cancer Res; 2002 Jun; 21(2):203-11. PubMed ID: 12148579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis.
    Vivona AA; Shpitz B; Medline A; Bruce WR; Hay K; Ward MA; Stern HS; Gallinger S
    Carcinogenesis; 1993 Sep; 14(9):1777-81. PubMed ID: 8403199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diallyl sulfide enhances azoxymethane-induced preneoplasia in Fischer 344 rat colon.
    Delker DA; Papanikolaou A; Suhr YJ; Rosenberg DW
    Chem Biol Interact; 2000 Feb; 124(3):149-60. PubMed ID: 10728775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of high-risk and low-risk diets on aberrant crypt and colonic tumor formation in Fischer-344 rats.
    Shivapurkar N; Tang ZC; Alabaster O
    Carcinogenesis; 1992 May; 13(5):887-90. PubMed ID: 1316816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
    Wali RK; Khare S; Tretiakova M; Cohen G; Nguyen L; Hart J; Wang J; Wen M; Ramaswamy A; Joseph L; Sitrin M; Brasitus T; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1653-62. PubMed ID: 12496057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes.
    Hu Y; Le Leu RK; Young GP
    Mutat Res; 2009; 677(1-2):27-32. PubMed ID: 19442760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatic DNA alterations in azoxymethane-induced F344 rat colon tumors by random amplified polymorphic DNA analysis.
    Luceri C; De Filippo C; Caderni G; Gambacciani L; Salvadori M; Giannini A; Dolara P
    Carcinogenesis; 2000 Sep; 21(9):1753-6. PubMed ID: 10964108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of beta-carotene and wheat bran fiber on colonic aberrant crypt and tumor formation in rats exposed to azoxymethane and high dietary fat.
    Alabaster O; Tang Z; Frost A; Shivapurkar N
    Carcinogenesis; 1995 Jan; 16(1):127-32. PubMed ID: 7834797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis.
    Singh J; Kulkarni N; Kelloff G; Reddy BS
    Carcinogenesis; 1994 Jul; 15(7):1317-23. PubMed ID: 8033306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a ras gene mutation in azoxymethane-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer.
    Stopera SA; Murphy LC; Bird RP
    Carcinogenesis; 1992 Nov; 13(11):2081-5. PubMed ID: 1423879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
    Rao CV; Hirose Y; Indranie C; Reddy BS
    Cancer Res; 2001 Mar; 61(5):1927-33. PubMed ID: 11280748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of progression of aberrant crypt foci and colon tumor development by vitamin E and beta-carotene in rats on a high-risk diet.
    Shivapurkar N; Tang Z; Frost A; Alabaster O
    Cancer Lett; 1995 May; 91(1):125-32. PubMed ID: 7750087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of azoxymethane-induced rat colon aberrant crypt foci by dietary protocatechuic acid.
    Kawamori T; Tanaka T; Kojima T; Suzui M; Ohnishi M; Mori H
    Jpn J Cancer Res; 1994 Jul; 85(7):686-91. PubMed ID: 8071110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients.
    Shivapurkar N; Huang L; Ruggeri B; Swalsky PA; Bakker A; Finkelstein S; Frost A; Silverberg S
    Cancer Lett; 1997 May; 115(1):39-46. PubMed ID: 9097977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy restriction modulates the development of advanced preneoplastic lesions depending on the level of fat in the diet.
    Lasko CM; Good CK; Adam J; Bird RP
    Nutr Cancer; 1999; 33(1):69-75. PubMed ID: 10227046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous development of aberrant crypt foci in F344 rats.
    Furukawa F; Nishikawa A; Kitahori Y; Tanakamaru Z; Hirose M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):197-201. PubMed ID: 12148578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon.
    Zaidi NH; Pretlow TP; O'Riordan MA; Dumenco LL; Allay E; Gerson SL
    Carcinogenesis; 1995 Mar; 16(3):451-6. PubMed ID: 7697797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of aberrant crypt foci to apoptosis induced by azoxymethane in rats chronically fed cholic acid.
    Magnuson BA; Shirtliff N; Bird RP
    Carcinogenesis; 1994 Jul; 15(7):1459-62. PubMed ID: 8033325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.